| Literature DB >> 28491426 |
Roberta Sartori1, Silvia Colombo2.
Abstract
CASEEntities:
Year: 2016 PMID: 28491426 PMCID: PMC5362844 DOI: 10.1177/2055116916653616
Source DB: PubMed Journal: JFMS Open Rep ISSN: 2055-1169
Figure 1Erosive-ulcerative lesions on the ventral abdomen, perivulvar region and medial aspect of the front and hindlimbs of a 5-year-old, spayed female domestic shorthair cat
Figure 2Close-up of an erosive-ulcerative lesion due to epidermal detachment on the ventral abdomen
Figure 3Erosive-ulcerative and crusted lesions on the medial and lateral canthus of both eyes
Figure 4Light photomicrograph of a section of affected skin, showing suprabasal epidermal detachment and follicular atrophy. No sebaceous glands are detected (haematoxylin and eosin, bar = 200 µm)
Figure 5Light photomicrograph of a section of affected skin, showing apoptotic cells at various levels of the epidermis, vacuolar degeneration of basal cells and subepidermal mononuclear infiltrate (haematoxylin and eosin, bar = 50 µm)
Figure 6Epidermal necrosis due to confluence of multiple apoptotic cells (haematoxylin and eosin, bar = 50 µm)
Figure 7Lymphocytic infiltrate in the follicular infundibulum (haematoxylin and eosin, bar = 50 µm)
Details of the algorithm of drug causality for Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) (Algorithm of Drug Causality in Epidermal Necrolysis) applied to the case
| Criterion | Values | Rules to apply | Score |
|---|---|---|---|
| Delay from initial drug component intake to onset of reaction (index day) | Suggestive +3 | From 5–28 days | 3 |
| Compatible +2 | From 29–56 days | ||
| Likely +1 | From 1–4 days | ||
| Unlikely −1 | >56 days | ||
| Excluded −3 | Drug started on or after the index day | ||
| In case of previous reaction to the same drug, only changes for: | |||
| Drug present in the body on index day | Definite 0 | Drug continued up to index day or stopped at a time point <5 times the elimination half-life before the index day | 0 |
| Doubtful −1 | Drug stopped at a time point prior to the index day by >5 times the elimination half-life but liver or kidney function alterations or suspected drug interactions are present | ||
| Excluded −3 | Drug stopped at a time point prior to the index day by >5 times the elimination half-life, without liver or kidney function alterations or suspected drug interactions | ||
| Prechallenge/rechallenge | Positive specific for disease and drug: 4 | SJS/TEN after use of same drug | |
| Positive specific for disease or drug: 2 | SJS/TEN after use of similar drug or other reaction with same drug | ||
| Positive unspecific: 1 | Other reaction after use of similar drug | ||
| Not done/unknown | No known previous exposure to this drug | 0 | |
| Negative −2 | Exposure to this drug without any reaction (before or after reaction) | ||
| Dechallenge | Neutral 0 | Drug stopped (or unknown) | 0 |
| Negative −2 | Drug continued without harm | ||
| Type of drug (notoriety) | Strongly associated 3 | Drug of the ‘high risk’ list according to previous case-control studies | 3 |
| Associated 2 | Drug with definite but lower risk according to previous case-control studies | ||
| Suspected 1 | Several previous reports, ambiguous epidemiology results (drug ‘under surveillance’) | ||
| Unknown 0 | All other drugs including newly released ones | ||
| Not suspected −1 | No evidence of association from previous epidemiology study with sufficient number of exposed controls | ||
| Intermediate score = total of all previous criteria | |||
| Other cause | Possible −1 | Rank all drugs from highest to lowest intermediate score | |
| If at least one has an intermediate score >3, subtract 1 point from the score of each of the other drugs taken by the patient (another cause is more likely) | |||
| Final score −12 to 10 | 6 |
Modified from Sassolas et al[4]
<0, very unlikely; 0–1, unlikely; 2–3, possible; 4–5, probable; ⩾6, very probable